Navigation Links
Freeslate’s Biologics Formulation System Selected by Sanofi Pasteur to Improve Efficiency of Formulation Development
Date:8/21/2013

Sunnyvale, Calif. (PRWEB) August 21, 2013

Freeslate, Inc., the leading provider of high throughput research solutions, today announced that Sanofi Pasteur, the vaccines division of Sanofi, has purchased Freeslate’s Biologics Formulation System, a comprehensive solution for accelerating research in vaccine and protein formulation development. The system automates sample preparation, sample stressing, and formulation analysis, allowing for the development of stable, robust formulations significantly faster with reduced API consumption.

Based on the Freeslate Core Module 3 (CM3) automation platform, the Biologics Formulation System combines liquid dispense and controlled heating/cooling/mixing with new automated measurements of pH, viscosity, and particle counting. Integrated by Freeslate’s Lab Execution and Analysis (LEA) software suite, the system provides intuitive experiment design and allows for the control and data integration of a range of third party analytics including Dynamic Light Scatter (DLS), UV/VIS plate readers, and High Pressure Liquid Chromatography (HPLC), maximizing R&D productivity.

“We are excited to be selected by a global leader in vaccines and are pleased they recognize the value our tools bring to the advancement of formulation development,” said John S. Senaldi, President and CEO of Freeslate. “As demonstrated by the adoption of our systems in Europe and across the globe, combinatorial approaches to vaccine formulation development can significantly accelerate productivity.”

Freeslate has built strong capabilities around automated solutions addressing the complex problems of drug development. The company’s products enable customers to better manage capacity by performing and assessing formulations, minimize later stage reformulations by exploring a broader analytical space early in development, and manage data from orthogonal analytics to help drive informed decision making.

About Freeslate

Freeslate is a privately held company that provides products and related services for high throughput research. Based on its proprietary laboratory automation platforms, high throughput pressure reactors, and integrated Lab Execution and Analysis (LEA) software suite, the company enables dramatic gains in its customers’ productivity and innovation by delivering seamlessly integrated automation solutions. Freeslate leverages its scientific expertise through its team of Ph.D. scientists, engineers, and software developers with directly relevant experience in the industries it serves. Collaborating with customers for more than a decade, the business has provided high throughput research solutions for the pharmaceutical, chemical, and energy industries. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit http://www.freeslate.com.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11038030.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BiologicsMD, Inc. Announces Issuance of First U.S. Patent for PTH-CBD™
2. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
3. Synthetic Biologics to Report Second Quarter 2013 Financial Results
4. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
5. Synthetic Biologics to Present at OneMedForum New York 2013
6. Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
7. Predictive Biomarker Discovery for Oncology Small-Molecules and Biologics - a Webinar Hosted by Xtalks
8. Genedata Biologics for Biopharma R&D at Ninth Annual PEGS
9. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
10. As the life science industry evolves, it is clear that biologics are here to stay!
11. Seminar Spotlights Key Trends in Biologics and Biosimilars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... Microbial genomics leader ... grant award has been made to Dr. Renato Polimanti of Yale University School ... the oral microbiome. Grant proposals have been vetted by the company’s scientific review ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation ... and lumbar disc production, company President, Jake Lubinski will be traveling to Switzerland ... AxioMed disc in Bern, Lucerne, and Zurich to discuss the benefits of a ...
(Date:12/2/2016)... , Dec. 2, 2016 Amgen (NASDAQ: ... ) today announced the submission of a Marketing Authorization Application ... a biosimilar candidate to Avastin ® (bevacizumab). The companies ... to the EMA. "The submission of ABP ... seeks to expand our oncology portfolio," said Sean E. ...
(Date:12/2/2016)... ... 01, 2016 , ... ACEA Biosciences, Inc. announced today that it will be ... at the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December ... clinical trials for AC0010 in patients with advanced non-small cell lung cancer harboring the ...
Breaking Biology Technology:
(Date:11/15/2016)... Research and Markets has announced the addition of the ... their offering. ... The global bioinformatics market ... 6.21 Billion in 2016, growing at a CAGR of 21.1% during ... is driven by the growing demand for nucleic acid and protein ...
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
(Date:6/22/2016)... WASHINGTON , June 22, 2016 On ... highly-anticipated call to industry to share solutions for the ... by U.S. Customs and Border Protection (CBP), explains that ... nationals are departing the United States ... criminals, and to defeat imposters. Logo - ...
Breaking Biology News(10 mins):